Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

References

• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205.
   PubMed Web of Science ®Google Scholar
• Bourgeois FT, Shannon MW, Valim C, et al. Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf. 2010;19(9):901–910.
   PubMed Web of Science ®Google Scholar
• Leroy F, Dauxois J-Y, Théophile H, et al. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases. BMC Med Res Methodol. 2014;14:17.
   PubMed Web of Science ®Google Scholar
• Biagi C, Montanaro N, Buccellato E, et al. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69(2):237–244.
   PubMed Web of Science ®Google Scholar
• FDA. FDA Adverse Event Reporting System (FAERS) statistics. 2016 Mar 2. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm
   Google Scholar
• FDA. Questions and answers on FDA’s Adverse Event Reporting System (FAERS). 2016 Mar 2. Available from: http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/
   Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10(7):796–803.
   PubMed Web of Science ®Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396.
   PubMed Web of Science ®Google Scholar
• Heeley E, Riley J, Layton D, et al. Prescription-event monitoring and reporting of adverse drug reactions. Lancet. 2001;358(9296):1872–1873.
   PubMed Web of Science ®Google Scholar
• Martin RM, Kapoor KV, Wilton LV, et al. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. BMJ. 1998;317(7151):119–120.
   PubMed Web of Science ®Google Scholar
• FDA. Requests for waivers to postmarketing safety reporting requirements. [cited 2016 Apr 7]. Available from: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074850.htm#requestsforwaiverstopostmarketingsafetyreportingrequirements
   Google Scholar
• Medical Dictionary for Regulatory Activities. Standardised MedDRA queries. 2015 [cited 2015 Jan 3]. Available from: http://www.meddra.org/standardised-meddra-queries
   Google Scholar
• MedDRA. 2017 Feb 21. Available from: http://www.meddra.org/
   Google Scholar
• Mozzicato P. Standardised MedDRA queries: their role in signal detection. Drug Safety. 2007;30(7):617–620.
   PubMed Web of Science ®Google Scholar
• Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc. 2012;19(2):212–218.
   PubMed Web of Science ®Google Scholar
• Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997;79(11):1475–1481.
   PubMed Web of Science ®Google Scholar
• Brown WV, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J. 2002;144(6):1036–1043.
   PubMed Web of Science ®Google Scholar
• O’Rourke B, Rourke B, Barbir M, et al. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study. Int J Cardiol. 2004;94(2–3):235–240.
   PubMed Web of Science ®Google Scholar
• Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, et al. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008;3(1):33.
   PubMed Web of Science ®Google Scholar
• Mullins CD, Seal B, Seoane-Vazquez E, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: medicare, medicaid and other US government payers perspectives: the ISPOR drug cost task force report-part IV. Value Health. 2010;13(1):18–24.
   PubMed Web of Science ®Google Scholar
• Mevacor (lovastatin) [package insert]. Whitehouse Station (NJ): Merck & Co. Inc; 2014 Feb [cited 2015 Aug 3]. Available from: https://www.merck.com/product/usa/pi_circulars/m/mevacor/mevacor_pi.pdf
   Google Scholar
• Pravachol (pravastatin) [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2013 Aug [cited 2015 Aug 3]. Available from: http://packageinserts.bms.com/pi/pi_pravachol.pdf
   Google Scholar
• Visaria J, Seoane-Vazquez E, Rodriguez-Monguio R, et al. Evaluating differences in drug reimbursement between mail-order and community pharmacy. Value Health. 2009;12(3):A88–A88.
   PubMed Web of Science ®Google Scholar
• Zocor (simvastatin) [package insert]. Whitehouse Station (NJ): Merck & Co. Inc; 2015 Mar [cited 2015 Aug 3]. Available from: http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf
   Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325–1334.
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–688 e1.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Matucci-Cerinic M, Mariette X, et al. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study. Arthritis Res Ther. 2014;16(1):R24.
   PubMed Web of Science ®Google Scholar
• Dewint P, Hansen BE, Verhey E, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut. 2014;63(2):292–299.
   PubMed Web of Science ®Google Scholar
• Kennedy WP, Simon JA, Offutt C, et al. Efficacy and safety of pateclizumab (anti-lymphotoxin-alpha) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res Ther. 2014;16(5):467.
   PubMed Web of Science ®Google Scholar
• Remicade (infliximab) [package insert]. Malvern: Centocor, Inc; 2015 Aug [cited 2015 Oct]. Available from: https://www.remicade.com/shared/product/remicade/prescribing-information.pdf
   Google Scholar
• Enbrel (etanercept) [package insert]. Thousand Oaks (CA): Immunex; 2015 Mar [cited 2015 Sep 21]. Available from: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf
   Google Scholar
• Seoane-Vazquez E, Rodriguez-Monguio R, Visaria J. The impact of mail order pharmacy in drug utilization and reimbursement in a large retirement system. Value Health. 2007;10(3):A24–A24.
   Web of Science ®Google Scholar
• Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–1441.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011;10(10):881–890.
   PubMed Web of Science ®Google Scholar
• Richens A, Davidson DL, Cartlidge NE, et al. A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. Adult EPITEG Collaborative Group. J Neurol Neurosurg Psychiatry. 1994;57(6):682–687.
   PubMed Web of Science ®Google Scholar
• Lexi-comp online. Hudson (OH): Lexi-Comp Inc. [cited 2015 Aug 15] Available from: http://online.lexi.com/lco/action/home/.
   Google Scholar
• Alvarez-Requejo A, Carvajal A, Bégaud B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483–488.
   PubMed Web of Science ®Google Scholar
• Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf. 2000;23(2):165–172.
   PubMed Web of Science ®Google Scholar
• Moride Y, Haramburu F, Requejo AA, et al. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 1997;43(2):177–181.
   PubMed Web of Science ®Google Scholar
• Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28(11):981–1007.
   PubMed Web of Science ®Google Scholar
• CEVR. The center for the evaluation of value and risk in health. [cited 2016 Apr 6]. Available from: https://research.tufts-nemc.org/cear4/AboutUs/WhoisCEVR.aspx
   Google Scholar
• Prevots DR, Sutter RW, Strebel PM, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Arch Pediatr Adolesc Med. 1994;148(5):479–485.
   PubMedGoogle Scholar
• Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167(16):1752–1759.
   PubMed Web of Science ®Google Scholar
• Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–294.
   PubMed Web of Science ®Google Scholar